MTOR and breast cancer: Breast cancer patients possess numerous genomic aberrations, many of which converge on several pathways involved in cancer cell signal transduction, such as phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) and the extracellular signal-regulated kinase (ERK) cascades [12].